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Predictive models within epilepsy are frequently developed via Cox’s proportional hazards models. 20 
These models estimate risk of a specified event such as 12-month remission or treatment failure. They 21 
are relatively simple to produce, have familiar output, and are particularly useful to answer questions 22 
about short-term prognosis. However, the Cox model only considers time to first event rather than all 23 
seizures after starting treatment for example. This makes assessing change in seizure rates over time 24 
difficult. Variants to the Cox model exist enabling recurrent events, such as seizures, to be modelled.  25 
One such variant is the Prentice, Williams and Peterson – Total Time (PWP-TT) model. An alternative 26 
is the negative binomial model for event counts. This study aims to demonstrate the differences 27 
between the three approaches, and to consider the benefits of the PWP-TT approach for assessing 28 
change in seizure rates over time. 29 
Methods 30 
Time to 12-month remission and time to first seizure after randomisation were modelled using the 31 
Cox model. Risk of seizure recurrence was modelled using the PWP-TT model, including all seizures 32 
across the whole follow-up period not just those occurring prior to the specified time point. Seizure 33 
counts were modelled using negative binomial regression. Differences between the approaches were 34 
demonstrated using participants recruited to the UK-based multi-centre Standard versus New 35 
Antiepileptic Drug (SANAD) study. 36 
Results 37 
Results from the PWP-TT model were similar to those from the conventional Cox and negative 38 
binomial models. In general, the direction of effect was consistent although the variables included in 39 
the models and the significance of the predictors varied. The confidence intervals obtained via the 40 
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PWP-TT model tended to be narrower due to the increase in statistical power of the model over the 41 
Cox and negative binomial models. 42 
Conclusions 43 
The Cox model is useful for determining the initial response to treatment and potentially informing 44 
when the next intervention may be required and the negative binomial model is useful for modelling 45 
event counts. The PWP-TT model extends the Cox model to all included events, not just the first. This 46 
is useful in determining the longer-term effects of treatment policy. Such a model should be 47 
considered when designing future clinical trials in medical conditions typified by recurrent events to 48 
improve efficiency and statistical power as well as providing evidence regarding changes in event rates 49 
over time.  50 
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Background 55 
Epilepsy is defined as the tendency to have recurrent unprovoked seizures, and is one of the most 56 
prevalent chronic neurological conditions affecting approximately 70 million people worldwide.(1) In 57 
clinical practice a key aim of treatment is to achieve freedom from seizures with minimal adverse 58 
effects from antiepileptic drugs. 59 
Standard internationally recognised outcomes in epilepsy include time to 12-month remission and 60 
time to treatment failure (2), and are most frequently modelled via Cox proportional hazards models. 61 
These models estimate risk of a specified event, are relatively simple to fit and have easily 62 
interpretable output. They are particularly useful to assess clinically relevant outcomes such as time 63 
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to first seizure after commencement of treatment, as that is the time at which a change in treatment 64 
may happen.  65 
The Cox model has notable disadvantages. In particular, it models time to one particular event after 66 
time zero such as time to 12-month remission from seizures, rather than modelling each seizure that 67 
occurs after randomisation in a clinical trial. Indeed, estimates suggest that 60 to 70% of people with 68 
epilepsy will achieve a remission from seizures.(3) However, up to 37% of people who achieve 69 
remission may proceed to have at least one further seizure whilst on antiepileptic drugs.(4) 70 
Considering time to first event only could limit the assessment of treatment policy and the ability to 71 
provide patients with an up-to-date prognosis following seizure occurrence. 72 
When the event of interest, such as a seizure in epilepsy, can occur more than once in a participant, 73 
the events are termed recurrent events. Several approaches have been proposed to account for intra-74 
subject correlation that arises from multiple events in survival analysis. These include variants to the 75 
Cox model.(5, 6) The most appropriate of these, based on the model assumptions and the clinical 76 
reality that seizures cluster and thus may not occur independently (7), is the Prentice, Williams and 77 
Peterson – Total Time (PWP-TT) model.(8)  The PWP-TT model considers cumulative time since 78 
randomisation per event. An alternative is modelling event counts which can be done using negative 79 
binomial regression modelling. 80 
Results from these three models have different interpretations. Cox models describe the risk of a 81 
specified event i.e. the first seizure after randomisation, or the first period of 12-month remission 82 
from seizures following randomisation. From a clinical perspective this is helpful to estimate when the 83 
next event of interest might happen from time zero. The PWP-TT and negative binomial models 84 
describe the rate of the event (i.e. number of events over a fixed time period) and can be used to 85 
assess the impact of longer-term policy on seizure frequency, as well as remission, within epilepsy.  86 
The aim of this paper is to demonstrate the differences between the three approaches, and to 87 
highlight the benefits of the PWP-TT approach for assessing change in seizure rates over time. Included 88 
5 
 
participants were those recruited to the UK-based multi-centre Standard versus New Antiepileptic 89 
Drug (SANAD) study.  90 
Methods 91 
Patients and Procedures 92 
Full details of the SANAD study are available in the original trial publications.(9, 10) Briefly, participants 93 
were eligible for randomisation into the SANAD study if they had a history of two or more clinically 94 
definite unprovoked epileptic seizures in the previous year. They were recruited to arm A if the 95 
recruiting clinician regarded carbamazepine the better standard treatment option than valproate, and 96 
arm B if the recruiting clinician regarded valproate the better standard treatment option than 97 
carbamazepine. In arm A, between 1st December 1999 and 1st June 2001, participants were allocated 98 
in a ratio of 1:1:1:1 to receive carbamazepine, gabapentin, lamotrigine or topiramate. From 1st June 99 
2001 to 31st August 2004, an oxcarbazepine group was added to the trial and participants were 100 
randomly allocated in a ratio of 1:1:1:1:1 to receive carbamazepine, gabapentin, lamotrigine, 101 
oxcarbazepine, or topiramate. Within arm B, participants were allocated randomly in a 1:1:1 ratio to 102 
valproate, lamotrigine or topiramate between 12th January 1999 and 31st August 2004. 103 
The primary outcomes across the SANAD study were time to treatment failure and time to 12 months 104 
of remission from seizures. Secondary outcomes included time to first post-randomisation seizure. 105 
Statistical Modelling 106 
Cox’s proportional hazards regression model was used to model time to first seizure post 107 
randomisation and time to 12-month remission as these are frequently reported outcomes within the 108 
clinical literature. Full details of the methodology used to develop the prognostic model for time to 109 
12-month remission for participants in SANAD have been reported previously.(11, 12) Identical 110 
methods were used for time to first seizure from randomisation. In brief, a pool of potential prognostic 111 
factors was established and a multivariable Cox model was derived by backwards selection according 112 
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to Akaike’s Information Criterion.(13) Continuous variables were investigated using fractional 113 
polynomial transformations (14-17), and presented as post-hoc defined categorical variables with 114 
categories chosen based on knot positions for a spline model fit to the variable.(18) Similar 115 
methodology was used to model event counts, via the negative binomial model. 116 
The PWP-TT model was used to estimate the rate of recurrent seizures based on data collected over 117 
the full study. It is a multiple time-to-event approach to modelling the data and accounts for missing 118 
data via censoring.(19) It assumes that subjects cannot be at risk for say a fourth seizure until they 119 
have a third seizure, which is a valid clinical assumption within epilepsy. The PWP-TT model enables 120 
inclusion of all post-randomisation seizures, not just the first for example. As for the Cox models, 121 
variables from the pool of potential prognostic factors were included in a multivariable model via 122 
backwards selection according to Akaike’s Information Criterion,(13) and continuous covariates were 123 
assessed for best fit.  124 
The list of possible prognostic factors for inclusion in the models was developed based on clinical 125 
consensus and previous related publications (20, 21): gender, febrile seizure history, first degree 126 
relative with epilepsy, treatment history (antiepileptic drug treatment prior to randomisation), age at 127 
randomisation, annual rate of tonic-clonic seizures prior to randomisation (total number of tonic-128 
clonic seizures prior to randomisation divided by time from first seizure to randomisation), 129 
neurological insult (learning disabilities or a neurological deficit), electroencephalogram (EEG) result, 130 
and seizure type. EEG result was classified as normal, not done, non-specific abnormality, or 131 
epileptiform abnormality (focal or generalised spikes, or spike and slow wave activity). Additionally, 132 
focal epilepsy site of onset and CT or MRI scan result were also included in the pool of possible factors 133 
for arm A of the study. 134 
Treatment was forced into each model as all participants were treated at randomisation. As only 44 135 
participants were classified as having generalised epilepsy in arm A, and only 54 participants were 136 
classified as having focal epilepsy in arm B these participants were excluded from this analysis. 137 
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Therefore arm A included 1491 participants with focal epilepsy and 157 with unclassified epilepsy, and 138 
arm B included 464 participants with generalised epilepsy and 184 participants with unclassified 139 
epilepsy. The two arms were modelled separately.  140 
In the development of prognostic models for time to 12-month remission and time to treatment 141 
failure previously (11, 22), stratification was used to account for the late addition of oxcarbazepine to 142 
the arm A of the study. However, this was found to have little effect on the results (11) and so the 143 
stratification term was dropped to ensure that all drugs could be included in the PWP-TT and negative 144 
binomial models.  145 
The initial comparison between models used the data from arm A as it was the largest dataset. 146 
However, arm B data was also considered to determine the generalisability of the results. A number 147 
of sensitivity analyses were also considered, again to determine the generalisability of the results. In 148 
particular, in SANAD clinicians were free to prescribe any treatment they deemed appropriate after 149 
withdrawal of the randomised drug. Therefore, the dataset includes many possible drug combinations 150 
which adds complexity to the statistical model. Therefore two approaches were taken; include 151 
everyone, and censor people at the time when they come off their randomised drug. Additionally, 152 
sensitivity analyses considered recurrent tonic-clonic seizures only (arm A and B) and recurrent tonic-153 
clonic and complex partial seizures only (arm A).  154 
Results 155 
Seizure Characteristics 156 
Outcome data were available for 1648 participants in arm A and 637 in arm B.  443 arm A participants 157 
had zero seizures during follow-up and of these, 380 (86%) people were classified as having focal 158 
epilepsy.  200 arm B participants had zero seizures during follow-up and of these, 123 (62%) people 159 
were classified as having generalised epilepsy.  The annual rate of seizures, per seizure type, for 160 
participants with seizures post-randomisation in arms A and B can be seen in Figure 1. Arm A 161 
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participants had a median rate of about 10 seizures per year across the three seizure types. Arm B 162 
groups were more variable, but generally had higher seizure frequency. 163 
Arm A – Focal Epilepsy 164 
Table 1 summarises the effect of treatment on outcome according to each of the four models - two 165 
Cox, negative binomial and the PWP-TT. The difference in interpretation between the Cox and PWP-166 
TT models can be illustrated graphically as in Figure 2. This figure was generated based on the median 167 
time to first seizure per treatment group in the case of the Cox model (shown in black), and randomly 168 
generated times from the uniform distribution based on the median number of predicted seizures per 169 
treatment group based on the PWP-TT model (shown in red). Although carbamazepine, oxcarbazepine 170 
and topiramate have the longest times to first seizure, in the longer term oxcarbazepine shows a lower 171 
number of seizures than both carbamazepine and topiramate. As a rate of zero indicates remission, 172 
lower average seizures rates imply more people achieving remission.  173 
Table 1: Risk of seizure recurrence by treatment – arm A 174 
 Hazard Ratio (95% CI)  
Variable PWP-TT: Rate of 
recurrent seizures 
Cox: First seizure Cox: 12-month 
remission 
Negative binomial: 







0.97 (0.89, 1.07) 
0.98 (0.89, 1.08) 
0.91 (0.82, 1.02) 
1.06 (0.97, 1.17) 
1.00 
1.34 (1.13, 1.59) 
1.23 (1.04, 1.45) 
1.03 (0.84, 1.26) 
1.06 (0.90, 1.26) 
1.00 
0.76 (0.63, 0.91) 
0.91 (0.76, 1.09) 
1.03 (0.83, 1.28) 
0.84 (0.70, 1.01) 
1.00 
1.45 (1.06, 1.99) 
0.91 (0.67, 1.25) 
0.67 (0.46, 0.98) 
1.25 (0.91, 1.72) 
Intercept N/A N/A N/A -2.68 (-2.89, -2.45) 
 175 
According to the Cox models (Table 1), risk of first seizure and chance of not achieving 12-month 176 
remission are significantly higher on gabapentin than carbamazepine – chance of not achieving 12-177 
month remission is equivalent to 1 divided by the chance of the event. A short time to first seizure 178 
9 
 
implies a higher chance of not achieving 12 month remission, which is reflected in the two Cox models 179 
estimating gabapentin and lamotrigine to be less effective than carbamazepine. Median time to first 180 
seizure on lamotrigine is 37 days shorter than carbamazepine and median time to remission is 120 181 
days shorter on carbamazepine than on lamotrigine. These results are broadly in line with the negative 182 
binomial model which shows rate of seizures is significantly higher on gabapentin than carbamazepine 183 
and significantly lower on oxcarbazepine than carbamazepine. 184 
According to the PWP-TT model (Table 1), people on topiramate have a 6% higher rate of recurrent 185 
seizures than those on carbamazepine. The direction of the effect is generally opposite to that for the 186 
Cox models and none of the results are significant. Therefore, taking all four models into 187 
consideration, gabapentin and lamotrigine appear worse at delaying a first seizure than 188 
carbamazepine. In the longer term there is less difference between the treatment policies because if 189 
the first treatment does not work, it will be changed, and if necessary changed again, aiming for 190 
seizure control. The PWP-TT model better captures the longer term consequence of this treatment 191 
policy. The size of effect is closer to zero with narrower confidence intervals for the PWP-TT model 192 
than the results seen with the Cox and negative binomial models. This is because the statistical power 193 
is maximised in the PWP-TT model.(19)  194 
The multivariable PWP-TT model included all potential covariates except for age; the Cox and negative 195 
binomial models included fewer covariates as shown in Table 2. As the multivariable PWP-TT model is 196 
more powerful for rate of recurrent seizures, more potential covariates with narrower confidence 197 
intervals are included than with either Cox model. The Cox models did not include febrile seizure 198 
history, first degree relative with epilepsy and EEG result. The negative binomial model did include 199 
EEG result but additionally neurological insult, focal site of onset, and annual rate of seizures prior to 200 
randomisation  No drug has significantly higher seizure rates than carbamazepine, but gabapentin was 201 
significant in both Cox models and gabapentin was significant in the negative binomial model.  202 
Table 2 about here 203 
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The PWP-TT model estimated a 10% lower seizure recurrence rate among people with simple or 204 
complex partial seizures only compared to those with simple or complex partial seizures and 205 
generalised tonic-clonic seizures. People with uncertain seizure types had long-term seizure rates 206 
almost twice that of people with simple or complex partial seizures only. The results also suggest that 207 
people with a low rate of seizures prior to randomisation have a higher rate of recurrent seizures than 208 
those with higher rates prior to randomisation. 209 
The direction of the effect for most statistically significant variables was the same across models, with 210 
the PWP-TT coefficients shrunk towards one. Differences in direction of estimated effect are likely due 211 
to the different variables include in the multivariable model and the resulting effect on the 212 
interactions between these variables. 213 
A forest plot comparing median seizure counts (in blue) predicted from the PWP-TT model according 214 
to combinations of patient characteristics can be seen in Figure 3. The associated observed seizure 215 
counts are also included for comparison (in red). Gender is the most influential factor with women 216 
having higher predicted and observed seizure counts within two years of randomisation than men, 217 
and thus lowest chance of remission. 218 
Arm B – Generalised Epilepsy 219 
Table 3: Risk of seizure recurrence by treatment – arm B 220 
 Hazard Ratio (95% CI)  
Variable PWP-TT: Rate of 
recurrent seizures 
Cox: First seizure Cox: 12-month 
remission 
Negative binomial: 





1.12 (0.99, 1.26) 
1.13 (1.00, 1.29) 
1.00 
1.40 (1.12, 1.76) 
1.21 (0.97, 1.52) 
1.00 
0.75 (0.60, 0.93) 
0.87 (0.70, 1.08) 
1.00 
1.86 (1.15, 2.99) 
1.66 (1.03, 2.67) 




For comparison, identical analyses were considered using the data from arm B. Table 3 summarises 222 
the effect of treatment on outcome according to each of the four models.  223 
The difference in interpretation between the Cox and PWP-TT models is again illustrated graphically, 224 
in Figure 4. Although valproate has a slightly longer median time to remission than topiramate, in the 225 
longer term both valproate and topiramate lead to a lower number of seizures than lamotrigine. 226 
According to the Cox models, risk of first seizure and chance of not achieving 12-month remission 227 
(1/chance of remission) are significantly higher on lamotrigine than valproate. A short time to first 228 
seizure implies a higher chance of not achieving 12 month remission, which is reflected in the two Cox 229 
models estimating lamotrigine to be less effective than valproate. Rate of seizures are also higher on 230 
lamotrigine and topiramate than valproate according to the negative binomial model. 231 
According to the PWP-TT model, people on lamotrigine have a 12% higher rate of recurrent seizures 232 
than those on valproate on average, and 13% higher in participants on topiramate than on valproate. 233 
The direction of the effect is in agreement with that from the Cox models but only the result for 234 
topiramate is significant. Therefore, taking all four models into consideration, valproate is much better 235 
at delaying a first seizure than lamotrigine and topiramate, but in the longer term there is less 236 
difference in the effect of treatment policies on seizure rate and remission. Again, the size of the effect 237 
is closer to zero with narrower confidence intervals for the PWP-CP than the results seen with the Cox 238 
and negative binomial models as the power is maximised.  239 
As the multivariable PWP-TT model is more powerful for rate of recurrent seizures, more potential 240 
covariates with narrower confidence intervals are included than with either Cox model (Table 4). The 241 
Cox models did not include febrile seizure history or EEG result. The negative binomial included febrile 242 
seizure history but additionally excluded gender and annual rate of seizures prior to randomisation. 243 
Topiramate had significantly higher seizure rates than valproate, but was not significant in the Cox or 244 
negative binomial models. 245 
Table 4 about here 246 
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The PWP-TT estimated a 28% lower rate of recurrent seizures among people with a history of febrile 247 
seizures than those who did not have such a history, and participants with seizures after a period of 248 
remission had a lower rate than treatment naïve participants. People with a neurological insult and 249 
those on lamotrigine or topiramate had higher rates of recurrent seizures than those on valproate. 250 
Older participants (over 50) had seizure recurrence rates 13% lower than those aged less than eight. 251 
The PWP-TT results imply that valproate has a longer expected time to first seizure and shorter time 252 
to remission. The direction of the effect for most statistically significant variables was the same across 253 
models with the PWP-TT coefficients shrunk towards one. Differences in direction of estimated effect 254 
are again likely due to the different variables included in the multivariable model and the resulting 255 
effect on the interactions between these variables. 256 
A forest plot comparing median seizure counts (in blue) predicted from the PWP-TT model according 257 
to combinations of patient characteristics can be seen in Figure 5. The associated observed seizure 258 
counts are also included for comparison (in red). Age is the most influential factor with the youngest 259 
people having the highest predicted seizure count within two years of randomisation, and thus lowest 260 
chance of remission. 261 
Sensitivity Analyses – PWP-TT model 262 
Arm A – Focal Epilepsy 263 
Sensitivity analyses of the PWP-TT model with censoring at withdrawal of randomised drug, and based 264 
on specific recurrent seizure types for patients in arm A can be seen in Table 5. The results for 265 
recurrent tonic-clonic seizures only, and recurrent tonic-clonic and complex partial seizures only are 266 
the same suggesting that the predicted rate of these seizures is similar. Censoring at withdrawal of 267 
randomised drug has little effect on the results, although the direction of effect for gabapentin 268 
changes and the results for gabapentin and topiramate become significant when the model is 269 
unadjusted for any other variables. 270 
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Table 5: Risk of seizure recurrence by treatment - sensitivity analyses (arm A) 271 
 Hazard Ratio (95% CI) 


























1.19 (1.05, 1.36) 
0.94 (0.83, 1.07) 
0.83 (0.71, 0.97) 
1.18 (1.03, 1.34) 
1.00 
1.01 (0.87, 1.17) 
0.97 (0.84, 1.13) 
0.87 (0.71, 1.05) 
1.02 (0.87, 1.19) 
1.00 
1.02 (0.85, 1.23) 
0.83 (0.69, 0.99) 
0.75 (0.59, 0.96) 
0.99 (0.83, 1.19) 
1.00 
1.01 (0.87, 1.17) 
0.97 (0.84, 1.13) 
0.87 (0.71, 1.05) 
1.02 (0.87, 1.19) 
1.00 
1.02 (0.85, 1.23) 
0.83 (0.69, 0.99) 
0.75 (0.59, 0.96) 
0.99 (0.83, 1.19) 
 272 
The results for the multivariable PWP-TT models according to each sensitivity analysis can be seen in 273 
Table 6. In general fewer variables were included in the multivariable models than seen in the original 274 
PWP-TT model. The direction of effect is generally consistent with the original results. 275 
Table 6 about here 276 
Arm B – Generalised Epilepsy 277 
Table 7: Risk of seizure recurrence by treatment - sensitivity analyses (arm B) 278 
 Hazard Ratio (95% CI) 
Variable On randomised drug 
only 
Recurrent tonic-
clonic seizures only 
On randomised drug only & recurrent 





1.18 (1.01, 1.38) 
1.58 (1.33, 1.88) 
1.00 
1.26 (1.06, 1.51) 
1.24 (1.03, 1.49) 
1.00 
1.54 (1.23, 1.93) 
2.08 (1.64, 2.63) 
 279 
Sensitivity analyses of the PWP-TT model with censoring at withdrawal of randomised drug, and based 280 
on specific recurrent seizure types for patients in arm B can be seen in Table 7. The varying conditions 281 
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had little effect on the results which maintain their significance and direction. The results for the 282 
multivariable PWP-TT models according to each sensitivity analysis can be seen in Table 8. In general 283 
fewer variables were included in the models than seen originally. The direction of effect is generally 284 
consistent with the original results. 285 
Table 8 about here 286 
Discussion 287 
The PWP-TT model for focal epilepsy suggests that participants with a relative with epilepsy have a 288 
lower rate of recurrent seizures than people without such a relative, and that people with an abnormal 289 
CT/MRI scan results have a higher rate of recurrent seizures than those with a normal scan result.  290 
People with frontal lobe, other, or unclassified site of onset have a lower rate of recurrent seizures 291 
than people with temporal lobe site of onset. Additionally, people with simple or complex seizures 292 
with generalised tonic-clonic seizures, and people with uncertain seizure type have a higher rate of 293 
recurrent seizures than people with simple or complex partial seizures. Also, people with a higher rate 294 
of seizures before randomisation have a lower rate of recurrent seizures than those with a lower rate 295 
of seizures before randomisation. This final result is contrary to expectation but is due to an 296 
interaction with febrile seizure history (p-value: 0.03): the few people who had febrile seizures had 297 
higher pre-randomisation rates. This interaction term is not included in the model, as it vastly 298 
increases the complexity of the model interpretation. 299 
The PWP-TT model for generalised epilepsy suggests that participants restarting treatment following 300 
seizures after remission have a lower rate of recurrent seizures than treatment naïve participants, that 301 
young participants (less than or equal to seven) have a lower rate of recurrent seizures than those 302 
aged eight or above, and that people with neurological insult have a higher rate of recurrent seizures 303 
than those without such an insult. Additionally, participants with febrile seizure history have a lower 304 
rate of recurrent seizure those who did not have such a history. Clinical intuition would suggest that 305 
participants with a febrile history seizure have a poorer clinical outcome. However, a history of febrile 306 
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seizures is more often associated with focal epilepsy rather than generalised and unclassified as 307 
considered here.(11, 22) This, combined with the fact that only 8% of participants under consideration 308 
here had a history of febrile seizures, potentially explains this spurious finding.  309 
The results of the Cox models have been discussed previously.(11, 22) While it is not appropriate to 310 
directly compare the results from the PWP-CTT model with those for conventional Cox models, we 311 
found that the results were fairly similar. Similarly the results of the negative binomial models. In 312 
general the direction of effect was consistent even if the significance of the covariate was not. 313 
Observed differences are likely to result from the number of variables included in the model, the 314 
underlying baseline hazard function, and the statistical power of the models. In particular, traditional 315 
Cox models consider a specific event with a fixed underlying intensity function while the PWP-TT 316 
model enables the underlying intensity function to vary from event to event.(23)  317 
The PWP-TT model accounts for all events along a patients’ journey and models time between each 318 
event. It also has improved statistical power over the Cox and negative binomial models. The PWP-TT 319 
model additionally estimates risk of future recurrent events rather than just time to a specified event. 320 
However, the data set-up is quite complex and the size of the dataset can be very large, especially for 321 
clinical conditions with many recurrent events such as seizures in epilepsy. Additionally the addition 322 
precision of the PWP-TT model is mirrored by a slight reduction in the ease of interpretation of the 323 
output. 324 
A limitation of this analysis is the way the seizure data were collected within SANAD. Specifically, 325 
people were asked to report number of seizures since their previous appointment together with the 326 
date of the most recent seizure and first seizure since the last appointment. Therefore, dates of 327 
specific seizures were not collected. There is some evidence to suggest that seizures beget seizures.(7) 328 
However, we have not been able to investigate this further, specifically regarding treatment effect 329 
between the PWP-TT and negative binomial models, due to the limitations of this, and most routinely 330 
collected data within epilepsy trials. 331 
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Few published analyses of clinical data have utilised the PWP-TT model. Those that have include an 332 
analysis of diarrhoeal episodes in children (24), a population-based study of repetitive traumatic brain 333 
injury among persons with traumatic brain injury (25), recurrent malaria episodes (26), and childhood 334 
infectious diseases.(6) Such a model should be considered when designing future clinical trials in 335 
medical conditions typified by recurrent events, to ensure improve efficiency and statistical power as 336 
well as providing evidence regarding changes in event rates over time.  337 
Conclusions 338 
Cox’s proportional hazard model is frequently used within the clinical literature to model time to a 339 
specified event. As demonstrated in this manuscript, this is useful for determining the initial response 340 
to treatment and potentially informing when the next intervention may be required. A variant on the 341 
Cox model, the PWP-TT, extends the Cox model to consider all events, not just the first. An alternative 342 
is the negative binomial model which considers event counts. We have shown the PWP-TT model to 343 
be useful to determine the longer-term effects of treatment policy. The PWP-TT model is therefore 344 
useful to increase understanding of chronic diseases. 345 
Further work is now required to validate these epilepsy models in alternative data. The most relevant 346 
independent data will be the results from the SANAD II study which are not due to be released until 347 
the end of 2019 at the earliest.  348 
Abbreviations 349 
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Tables 453 
Table 2: PWP-TT, Cox and negative binomial models for participants in arm A of SANAD 454 
 Hazard Ratio (95% CI)  




Cox PH:  
First seizure 








0.94 (0.89, 1.00) 
1.00 
0.84 (0.75, 0.94) 
1.00 
1.22 (1.07, 1.38) 
1.00 







1.06 (0.93, 1.20) 







0.88 (0.80, 0.97) 









0.92 (0.70, 1.22) 
 
1.04 (0.96, 1.11) 
1.00 
1.02 (0.70, 1.47) 
 
1.59 (1.37, 1.85) 
1.00 
0.87 (0.58, 1.30) 
 










1.07 (0.98, 1.17) 
1.00 
1.20 (1.01, 1.42) 
1.00 
0.78 (0.63, 0.97) 
N/A 




1.01 (0.94, 1.09) 
 
1.01 (0.93, 1.11) 
N/A N/A 1.00 
1.24 (0.86, 1.82) 
 








0.95 (0.85, 1.07) 
 
0.95 (0.73, 1.23) 







1.10 (1.02, 1.18) 
0.93 (0.85, 1.02) 
N/A 1.00 
0.89 (0.77, 1.04) 
1.16 (0.97, 1.38) 
N/A 








0.98 (0.91, 1.05) 
0.84 (0.73, 0.96) 
0.83 (0.71, 0.96) 
0.50 (0.29, 0.86) 
N/A 1.00 
0.93 (0.80, 1.07) 
1.18 (0.91, 1.54) 
1.26 (0.97, 1.65) 












0.99 (0.99, 1.00) 
0.99 (0.98, 0.99) 
0.98 (0.97, 0.99) 
0.97 (0.96, 0.99) 
0.97 (0.95, 0.99) 
1.00 
1.01 (1.00, 1.01) 
1.01 (1.00, 1.02) 
1.02 (1.01, 1.03) 
1.03 (1.01, 1.04) 
1.03 (1.01, 1.05) 
1.00 
0.91 (0.86, 0.96) 
0.81 (0.71, 0.92) 
0.71 (059, 0.87) 
0.61 (0.45, 0.82) 












0.98 (0.96, 0.99) 
0.96 (0.94, 0.99) 
0.95 (0.92, 0.98) 
0.93 (0.88, 0.97) 
0.89 (0.83, 0.96) 
1.00 
1.15 (1.12, 1.18) 
1.26 (1.21, 1.32) 
1.37 (1.30, 1.45) 
1.61 (1.48, 1.75) 
2.06 (1.82, 2.34) 
1.00 
0.86 (0.83, 0.90) 
0.75 (0.69, 0.81) 
0.60 (0.52, 0.69) 
0.52 (0.43, 0.63) 
0.45 (0.36, 0.56) 
N/A 
Seizure type Simple or complex 
partial 































0.97 (0.88, 1.06) 
0.98 (0.89, 1.08) 
0.92 (0.82, 1.02) 
1.06 (0.97, 1.17) 
1.00 
1.42 (1.20, 1.68) 
1.26 (1.07, 1.50) 
1.11 (0.90, 1.36) 
1.08 (0.91, 1.28) 
1.00 
0.73 (0.60, 0.87) 
0.89 (0.74, 1.06) 
0.98 (0.79, 1.22) 
0.82 (0.68, 0.99) 
1.00 
1.41 (1.03, 1.93) 
1.02 (0.74, 1.39) 
0.80 (0.56, 1.17) 
1.13 (0.83, 1.53) 
Intercept N/A N/A N/A -2.17 (-2.62, -1.71) 
N/A – variable not included in multivariable model 455 
  456 
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Table 4: PWP-TT,  Cox and negative binomial models for participants in arm B of SANAD 457 
 Hazard Ratio (95% CI)  




Cox PH:  
First seizure 








1.09 (0.99, 1.20) 
1.00 








0.72 (0.63, 0.82) 
N/A N/A 1.00 







1.11 (0.96, 1.28) 
1.00 
1.28 (1.01, 1.61) 
1.00 
0.71 (0.56, 0.91) 
1.00 









0.74 (0.59, 0.92) 
 
1.18 (0.99, 1.41) 
N/A 1.00 
0.85 (0.52, 1.41) 
 
0.79 (0.49, 1.00) 
1.00 
0.77 (0.30, 2.36) 
 






1.38 (1.23, 1.55) 
1.00 
1.27 (0.95, 1.70) 
1.00 
0.64 (0.47, 0.87) 
1.00 
2.84 (1.56, 5.53) 








1.02 (0.90, 1.15) 
 
0.83 (0.67, 1.03) 
 
0.78 (0.61, 0.99) 





1.17 (1.05, 1.31) 
1.16 (1.02, 1.31) 
1.00 
1.53 (1.22, 1.93) 
1.23 (0.98, 1.55) 
1.00 
0.79 (0.64, 0.99) 
0.92 (0.74, 1.14) 
1.00 
1.02 (0.65, 1.61) 













0.97 (0.95, 0.99) 
0.95 (0.90, 0.99) 
0.93 (0.87, 0.99) 
0.90 (0.82, 0.98) 
0.87 (0.78, 0.97) 
1.00 
0.93 (0.89, 0.97) 
0.87 (0.80, 0.95) 
0.83 (0.74, 0.93) 
0.77 (0.66, 0.91) 
0.72 (0.59, 0.89) 
N/A 1.00 
0.82 (0.77, 0.88) 
0.62 (0.53, 0.72) 
0.44 (0.34, 0.57) 
0.21 (0.12, 0.35) 
0.07 (0.02, 0.16) 










1.02 (0.99, 1.06) 
1.05 (0.98, 1.11) 
1.09 (0.97, 1.21) 
N/A N/A 
Seizure type Generalised tonic-
clonic 
Absence 






0.85 (0.72, 1.01) 
1.05 (0.90, 1.23) 
 
 
1.05 (0.90, 1.23) 
 
0.87 (0.74, 1.03) 
1.00 
3.34 (1.98, 5.63) 
2.18 (1.67, 2.84) 
 
 
1.16 (0.88, 1.53) 
 
2.63 (1.70, 4.08) 
1.00 
0.62 (0.47, 0.81) 
0.56 (0.43, 0.72) 
 
 
0.83 (0.65, 1.05) 
 
0.58 (0.39, 0.86) 
1.00 
1.52 (6.70, 21.16) 
6.34 (3.82, 10.61) 
 
 
1.42 (0.88, 2.32) 
 
4.77 (2.22, 11.42) 
Intercept N/A N/A N/A -3.03  
(-3.77, -2.77) 
N/A – variable not included in multivariable model 458 
  459 
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Table 6: Sensitivity analysis of the PWP-TT model (arm A) 460 
 Hazard Ratio (95% CI) 























0.88 (0.85, 0.91) 
1.00 
0.84 (0.80, 0.88) 
1.00 
0.88 (0.85, 0.91) 
1.00 





N/A N/A 1.00 
1.11 (0.99, 1.25) 
N/A 1.00 







0.88 (0.84, 0.93) 
1.00 
0.93 (0.86, 1.00) 
1.00 
0.88 (0.84, 0.93) 
1.00 








0.94 (0.85, 1.03) 
1.05 (1.01, 1.09) 
1.00 
0.77 (0.70, 0.86) 
1.01 (0.98, 1.05) 
1.00 
1.30 (1.11, 1.52) 
1.02 (0.96, 1.08) 
1.00 
0.77 (0.70, 0.86) 
1.01 (0.98, 1.05) 
1.00 
1.30 (1.11, 1.52) 





N/A N/A N/A N/A N/A 





0.80 (0.76, 0.84) 
0.88 (0.84, 0.92) 
1.04 (1.01, 1.08) 
1.00 
0.94 (0.88, 1.00) 
0.93 (0.88, 0.98) 
0.97 (0.93, 1.02) 
1.00 
0.93 (0.83, 1.03) 
0.90 (0.84, 0.97) 
1.09 (1.02, 1.16) 
1.00 
0.94 (0.88, 1.00) 
0.93 (0.88, 0.98) 
0.97 (0.93, 1.02) 
1.00 
0.93 (0.83, 1.03) 
0.90 (0.84, 0.97) 
1.09 (1.02, 1.16) 






1.05 (1.01, 1.08) 
0.95 (0.91, 0.99) 
1.00 
1.17 (1.12, 1.22) 
1.10 (1.04, 1.16) 
1.00 
1.03 (0.98, 1.10) 
1.16 (1.08, 1.25) 
1.00 
1.17 (1.12, 1.22) 
1.10 (1.04, 1.16) 
1.00 
1.03 (0.98, 1.10) 
1.16 (1.08, 1.25) 








1.06 (1.03, 1.10) 
1.29 (1.22, 1.37) 
0.84 (0.79, 0.90) 
0.43 (0.30, 0.60) 
1.00 
1.05 (1.01, 1.09) 
0.93 (0.86, 1.00) 
1.01 (0.93, 1.09) 
0.39 (0.30, 0.50) 
1.00 
0.98 (0.93, 1.04) 
0.85 (0.76, 0.96) 
0.94 (0.84, 1.05) 
0.44 (0.29, 0.67) 
1.00 
1.05 (1.01, 1.09) 
0.93 (0.86, 1.00) 
1.01 (0.30, 0.50) 
0.39 (0.93, 1.02) 
1.00 
0.98 (0.93, 1.04) 
0.85 (0.76, 0.96) 
0.94 (0.84, 1.05) 













1.01 (1.00, 1.01) 
1.01 (1.00, 1.02) 
1.02 (1.00, 1.03) 
1.02 (1.00, 1.05) 
1.03 (1.00, 1.06) 












1.01 (1.00, 1.01) 
1.01 (1.00, 1.02) 
1.02 (1.00, 1.03) 
1.03 (1.00, 1.05) 
1.04 (1.01, 1.07) 
N/A 1.00 
1.04 (1.02, 1.05) 
1.06 (1.04, 1.08) 
1.08 (1.05, 1.11) 
1.13 (1.08, 1.17) 
1.17 (1.11, 1.23) 
N/A 1.00 
1.04 (1.02, 1.05) 
1.06 (1.04, 1.08) 
1.08 (1.05, 1.11) 
1.13 (1.08, 1.17) 
1.17 (1.11, 1.23) 
Seizure type S/C partial 
S/C + gen. TC 
 Uncertain 
1.00 
0.96 (0.94, 0.99) 
2.05 (1.47, 2.87) 
1.00 
0.84 (0.80, 0.88) 
2.03 (1.57, 2.62) 
1.00 
1.05 (0.98, 1.13) 
2.06 (1.36, 3.13) 
1.00 
0.84 (0.80, 0.88) 
2.03 (1.57, 2.62) 
1.00 
1.05 (0.98, 1.13) 







1.20 (1.15, 1.25) 
0.94 (0.90, 0.97) 
0.84 (0.79, 0.89) 
1.15 (1.11, 1.20) 
1.00 
0.98 (0.93, 1.03) 
0.95 (0.90, 1.01) 
0.85 (0.80, 0.91) 
0.97 (0.80, 0.88) 
1.00 
1.05 (0.97, 1.14) 
0.86 (0.80, 0.93) 
0.75 (0.68, 0.83) 
1.01 (0.93, 1.09) 
1.00 
0.98 (0.93, 1.03) 
0.95 (0.90, 1.01) 
0.85 (0.80, 0.91) 
0.97 (0.92, 1.03) 
1.00 
1.05 (0.97, 1.14) 
0.86 (0.80, 0.93) 
0.75 (0.68, 0.83) 
1.01 (0.93, 1.09) 
N/A – variable not included in multivariable model; Epi. abnorm. – epileptiform abnormality; 461 
N/S abnorm. – non-specific abnormality; S/C – simple or complex; gen. TC – generalised tonic-clonic 462 
 463 
  464 
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Table 8: Sensitivity analysis of the PWP-TT model (arm B) 465 
 Hazard Ratio (95% CI) 




On randomised drug 
only & recurrent tonic-




1.29 (1.22, 1.36) 
1.00 
1.29 (1.19, 1.39) 
1.00 
1.28 (1.14, 1.44) 
Febrile Seizure History Absent 
Present 
N/A 1.00 
0.82 (0.71, 0.95) 
1.00 
1.33 (1.09, 1.63) 





1.21 (1.14, 1.30) 
N/A 1.00 
1.55 (1.37, 1.75) 
Treatment History Treat. naïve 
Seizures 
Not SANAD AED 
1.00 
0.81 (0.68, 0.97) 
1.45 (1.31, 1.61) 
1.00 
0.68 (0.53, 0.87) 
1.08 (0.97, 1.21) 
1.00 
1.09 (0.79, 1.50) 
1.46 (1.24, 1.72) 
Neurological Insult Absent 
Present 
N/A 1.00 
1.17 (1.04, 1.31) 
1.00 
0.79 (0.66, 0.93) 





0.77 (0.64, 0.93) 
0.75 (0.65, 0.85) 
1.19 (1.11, 1.29) 
1.00 
0.74 (0.63, 0.87) 
0.61 (0.53, 0.70) 
0.83 (0.76, 0.91) 
1.00 
1.01 (0.75, 1.35) 
0.65 (0.54, 0.80) 
1.08 (0.95, 1.23) 









0.94 (0.93, 0.95) 
0.89 (0.87, 0.91) 
0.85 (0.82, 0.88) 
0.80 (0.76, 0.84) 
0.75 (0.71, 0.80) 
1.00 
0.96 (0.94, 0.97) 
0.92 (0.88, 0.95) 
0.89 (0.84, 0.93) 
0.85 (0.79, 0.91) 
0.81 (0.74, 0.89) 
1.00 
0.98 (0.95, 1.00) 
0.96 (0.91, 1.01) 
0.94 (0.88, 1.01) 
0.92 (0.84, 1.01) 
0.90 (0.80, 1.02) 








0.99 (0.98, 1.00) 
0.98 (0.96, 1.00) 
0.96 (0.92, 0.99) 
N/A 
Seizure type Gen. TC 
Absence 
Myo./Abs + TC 
Unclass. TC 
1.00 
1.14 (1.04, 1.26) 
1.12 (1.03, 1.22) 
1.00 (0.91, 1.11) 
1.00 
1.04 (0.84, 1.30) 
1.43 (1.30, 1.57) 
1.11 (1.00, 1.23) 
1.00 
0.88 (0.69, 1.12) 
1.51 (1.32, 1.73) 
1.02 (0.88, 1.18) 
29 
 





1.26 (1.18, 1.34) 
1.61 (1.50, 1.73) 
1.00 
1.24 (1.14, 1.36) 
1.29 (1.18, 1.42) 
1.00 
1.57 (1.38, 1.79) 
2.16 (1.88, 2.47) 
N/A – variable not included in multivariable model; Epi. abnorm. – epileptiform abnormality; 466 
N/S abnorm. – non-specific abnormality; gen. TC – generalised tonic-clonic; myo./abs + TC – 467 
myoclonic or absence with tonic-clonic; unclass. TC – unclassified tonic-clonic 468 
Figure Legends 469 
Figure 1: Box and whisker plots for total non-zero within-study seizures by seizure type, by study arm 470 
SP: simple partial; CP: complex partial; SCGTC: simple or complex partial with generalised tonic-clonic; 471 
M: myoclonic; TA: typical absence; AA: atypical absence; TC: generalised tonic-clonic; OTC: other tonic-472 
clonic 473 
Figure 2: Visualisation of the Cox and PWP-TT models according to treatment group – arm A  474 
Black lines and crosses shows median time to first seizure estimated from a Cox model, red lines and 475 
crosses represent randomly generated event times according the predicted number of events from 476 
the PWP-TT model 477 
 478 
Figure 3: Seizure counts from the PWP-TT model based on combinations of risk factors (arm A) 479 
Circles show median seizure counts while lines show interquartile ranges of seizure counts 480 
 481 
Figure 4: Visualisation of the Cox and PWP-TT models according to treatment group – arm B 482 
Black lines and crosses show median time to first seizure according to a Cox model; red lines and 483 
crosses represent randomly generated event times according the predicted number of events from 484 




Figure 5: Median and quartiles for seizure counts from the PWP-TT model for Arm B based on 487 
combinations of risk factors 488 
All participants are assumed to have no history of febrile seizures 489 
 490 
 491 
